“With 25 years of experience in the development, manufacturing, and global marketing of innovative diagnostic kits, Theradiag with its experienced team is strengthening its strategy for the development of theranostic kits. The increasing importance of biotherapies in treating autoimmune diseases and cancer requires the development of a new generation of diagnostics.

Theradiag met this challenge for two years with the 2011 launch of its new Lisa-Tracker panel which provides a better monitoring of patients treated by Anti-TNF. We will be intensifying this strategy and our researchers are currently developing new theranostic tests to meet clinician needs in order to improve treatment for their patients.

Our experience in marketing innovative diagnostics in more than 30 countries, and the expertise of our teams in association with our partners, will allow us to pursue our activity and successfully launch these new products.

Increasing sales of products developed and manufactured internally is proof of our dynamism and represents the basis of our future success.”